| Molecular recognition and docking algorithms N Brooijmans, ID Kuntz Annual review of biophysics and biomolecular structure 32 (1), 335-373, 2003 | 1103 | 2003 |
| Development and validation of a modular, extensible docking program: DOCK 5 DT Moustakas, PT Lang, S Pegg, E Pettersen, ID Kuntz, N Brooijmans, ... Journal of computer-aided molecular design 20, 601-619, 2006 | 545 | 2006 |
| First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway M Hagel, C Miduturu, M Sheets, N Rubin, W Weng, N Stransky, N Bifulco, ... Cancer discovery 5 (4), 424-437, 2015 | 307 | 2015 |
| Bis (morpholino-1, 3, 5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery … AM Venkatesan, CM Dehnhardt, E Delos Santos, Z Chen, O Dos Santos, ... Journal of medicinal chemistry 53 (6), 2636-2645, 2010 | 246 | 2010 |
| A precision therapy against cancers driven by KIT/PDGFRA mutations EK Evans, AK Gardino, JL Kim, BL Hodous, A Shutes, A Davis, XJ Zhu, ... Science translational medicine 9 (414), eaao1690, 2017 | 204 | 2017 |
| Kinase domain mutations in cancer: implications for small molecule drug design strategies JA Bikker, N Brooijmans, A Wissner, TS Mansour Journal of medicinal chemistry 52 (6), 1493-1509, 2009 | 197 | 2009 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent 8,802,697, 2014 | 133 | 2014 |
| ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines A Zask, JC Verheijen, K Curran, J Kaplan, DJ Richard, P Nowak, ... Journal of medicinal chemistry 52 (16), 5013-5016, 2009 | 114 | 2009 |
| Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors A Zask, J Kaplan, JC Verheijen, DJ Richard, K Curran, N Brooijmans, ... Journal of medicinal chemistry 52 (24), 7942-7945, 2009 | 112 | 2009 |
| Stability of macromolecular complexes N Brooijmans, KA Sharp, ID Kuntz Proteins: Structure, Function, and Bioinformatics 48 (4), 645-653, 2002 | 110 | 2002 |
| Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery PS Kutchukian, NY Vasilyeva, J Xu, MK Lindvall, MP Dillon, M Glick, ... PloS one 7 (11), e48476, 2012 | 89 | 2012 |
| Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402 CM Dehnhardt, AM Venkatesan, E Delos Santos, Z Chen, O Santos, ... Journal of medicinal chemistry 53 (2), 798-810, 2010 | 89 | 2010 |
| Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma MA Hatlen, O Schmidt-Kittler, CA Sherwin, E Rozsahegyi, N Rubin, ... Cancer discovery 9 (12), 1686-1695, 2019 | 86 | 2019 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent 9,126,951, 2015 | 83 | 2015 |
| Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors Z Chen, AM Venkatesan, CM Dehnhardt, S Ayral-Kaloustian, ... American Chemical Society, 2010 | 73 | 2010 |
| Principles and methods of docking and ligand design J Krumrine, F Raubacher, N Brooijmans, I Kuntz Structural bioinformatics 44, 441-476, 2003 | 67 | 2003 |
| Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase P Nowak, DC Cole, N Brooijmans, MG Bursavich, KJ Curran, ... Journal of medicinal chemistry 52 (22), 7081-7089, 2009 | 66 | 2009 |
| Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin … JC Verheijen, DJ Richard, K Curran, J Kaplan, M Lefever, P Nowak, ... Journal of medicinal chemistry 52 (24), 8010-8024, 2009 | 59 | 2009 |
| The intrinsic electrostatic potential and the intermediate ring of charge in the acetylcholine receptor channel GG Wilson, JM Pascual, N Brooijmans, D Murray, A Karlin The Journal of general physiology 115 (2), 93-106, 2000 | 58 | 2000 |
| Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer MS Eno, JD Brubaker, JE Campbell, C De Savi, TJ Guzi, BD Williams, ... Journal of medicinal chemistry 65 (14), 9662-9677, 2022 | 57 | 2022 |
